From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Open accessThe DOI matches its Crossref record; 155 of the 156 references it cites were found in a registry or an index.
Abstract
Although most same-stage non-alcoholic fatty liver disease (NAFLD) patients exhibit similar histologic sequelae, the underlying mechanisms appear to be highly heterogeneous. Therefore, it was recently proposed to redefine NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in which other known causes of liver disease such as alcohol consumption or viral hepatitis do not need to be excluded. Revised nomenclature envisions speeding up and facilitating anti-MAFLD drug development by means of patient stratification whereby each subgroup would benefit from distinct pharmacological interventions. As human-based in vitro research fulfils an irrefutable step in drug development, action should be taken as well in this stadium of the translational path. Indeed, most established in vitro NAFLD models rely on short-term exposure to fatty acids and use lipid accumulation as a phenotypic benchmark. This general approach to a seemingly ambiguous disease such as NAFLD therefore no longer seems applicable. Human-based in vitro models that accurately reflect distinct disease subgroups of MAFLD should thus be adopted in early preclinical disease modeling and drug testing. In this review article, we outline considerations for setting up translational in vitro experiments in the MAFLD era and allude to potential strategies to implement MAFLD heterogeneity into an in vitro setting so as to better align early drug development with future clinical trial designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Impact of MAFLD nomenclature on different stages of drug development. Until now, patient inclusion for anti-NAFLD clinical studies was based on hepatic phenotype in the absence of significant alcohol intake and concurring pathologies. Anti-MAFLD trials will be undertaken based on pathogenic determinants that will likely require distinct pharmacological interventions. Introduction of the MAFLD terminology requires deeper understanding of the pathogenesis of fatty liver disease and hence necessitates the development of human-based in vitro models able to represent the distinct disease subsets. Disease subsets of MAFLD are indicated by the blue, green, yellow and pink colors. Corresponding in vitro tests, in vivo models, stratification in clinical studies and distinct pharmacological interventions are visualized by the same color for each disease subset. [Abbreviations: MAFLD: Metabolic-dysfunction associated fatty liver disease, NAFLD: non-alcoholic fatty liver disease].](https://figures.cochat.ai/paper-figures/ecb27442ad8f4dc89e763090015f414b/from-nafld-to-mafld-aligning-translational-in-vitro-research-to-clinical-figure-1.jpg)

![Figure 3 Translation of MAFLD patient characteristics to an in vitro environment. Multiple factors contribute to the phenotypical presentation of MAFLD. Cells used for setting up in vitro MAFLD disease models may inherently exhibit disease modifiers that require proper documentation of their origin in the first instance. Well-established culture conditions including non-physiological cell culture medium composition and oxygen tension may also influence specific pathogenic mechanisms. [Abbreviations: LPS: lipopolysaccharide].](https://figures.cochat.ai/paper-figures/94cf7f5731574495be7b94a32458d2fb/from-nafld-to-mafld-aligning-translational-in-vitro-research-to-clinical-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“20%) and the global increase in NAFLD prevalence is consistent with the alarming rise of obesity prevalence worldwide [78].”
BackgroundThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“Obesity is one of the most common and well described risk factors for NAFLD [77].”
BackgroundSontrop, J. M., Dixon, S. N., Garg, A. X., Buendia-Jimenez, I., Dohein, O., Huang, S.-H. S., & Clark, W. F. (2013) · American Journal of Nephrology · doi:10.1159/000350377 · Cited by 5,871
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · cited 1×
“Hence, a patient suffering from any other liver disease and who also meets the criteria for diagnosis of MAFLD, should be defined as having dual (or more) etiology fatty liver disease [119].”
BackgroundMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 6×
“Clinical studies report drug-response rates ranging from 20–40% with placebo effects accounting for 10 to 20% [7,8], suggesting the presence of certain effect modifiers.”
BackgroundMethodInfluentialEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 10×
“In patients with metabolically unhealthy obesity, increased concentrations of IL-6 were found in VAT, suggesting increased pro-inflammatory activity of VAT [88,89].”
BackgroundInfluentialVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · cited 1×
“Weight loss through lifestyle modification, achieved through close follow-up by dieticians and physical activity, might be a cost-effective and efficient approach for treatment of NAFLD [9].”
BackgroundEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“On the other hand, since fibrosis is the most important determinant for disease-specific mortality in NAFLD [143], one might question the importance of detailed modeling of MAFLD subtypes in order to develop effective therapeutics.”
BackgroundHuman organoids: model systems for human biology and medicine
Kim, J., Koo, B.-K., & Knoblich, J. A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0259-3 · Cited by 2,187 · cited 1×
“Organoids [31] - Cell–cell interactions - Preservation of functional and metabolic activity over several weeks - Recapitulate developmental phases of the liver - Higher cost - Require scaffolds - High variability due to lack of standardized protocols - Limited options for genetic modification - Limited representation…”
Background
Research works printed but not linked: 1
- Liu, 2018, Abstract 682: TM6SF2 is necessary for the late addition of lipid and secretion of fully-lipidated very low density lipoproteins from Hepg2 cell, Arterioscler. Thromb. Vasc. Biol., 36, A682
Cited by
Kocas‐Kilicarslan, Z. N., Cetin, Z., Faccioli, L. A. P., Motomura, T., Amirneni, S., Díaz‐Aragon, R., Florentino, R. M., Sun, Y., Plá-Palacín, I., Xia, M., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.011 · Cited by 13
Verhoeven, A., Gatzios, A., Rodrigues, R. M., Sanz-Serrano, J., Kock, J. D., Vinken, M., & Vanhaecke, T. (2025) · Toxicology · doi:10.1016/j.tox.2025.154263 · Cited by 8
Self-citationThe HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 10
Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach
Palasantzas, V. E. J. M., Struik, D., Bos, T., Withoff, S., Fu, J., Jonker, J. W., & Hoogerland, J. A. (2026) · Nutrients · doi:10.3390/nu18030388 · Cited by 6
Zeng, M., Chen, L., Li, Y., Mi, Y., & Xu, L. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000085 · Cited by 5
Metadata
- Authors
- Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J.
- Affiliations
- Vrije Universiteit Brussel (BE)
- Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
- Corresponding author
- Gatzios, Alexandra
- Boeckmans, Joost
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2022-01-12
- Volume
- 10
- Issue
- 1
- Pages
- 161
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC8773802
- OpenAlex
- W4205757434
- Cited by
- 15
- References
- 156
- Citations by year
- 2026: 9 · 2025: 3 · 2023: 3
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research Foundation - Flanders (12H2216N, 1S73019N, G042019N)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, disease heterogeneity, in vitro disease model, patient stratification, translational research, preclinical drug testing, disease nomenclature
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. https://app.cochat.ai/papers/10.3390/biomedicines10010161
- The paper
- Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022). From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines. https://doi.org/10.3390/biomedicines10010161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.